Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study
Open Access
- 18 January 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Chemical Theory and Computation
- Vol. 13 (2) , 784-795
Abstract
Binding free energies of bromodomain inhibitors are calculated with recently formulated approaches, namely ESMACS (enhanced sampling of molecular dynamics with approximation of continuum solvent) and TIES (thermodynamic integration with enhanced sampling). A set of compounds is provided by GlaxoSmithKline, which represents a range of chemical functionality and binding affinities. The predicted binding free energies exhibit a good Spearman correlation of 0.78 with the experimental data from the 3-trajectory ESMACS, and an excellent correlation of 0.92 from the TIES approach where applicable. Given access to suitable high end computing resources and a high degree of automation, we can compute individual binding affinities in a few hours with precisions no greater than 0.2 kcal/mol for TIES, and no larger than 0.34 and 1.71 kcal/mol for the 1- and 3-trajectory ESMACS approaches.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/I017909/1)
- Medical Research Council (MR/L016311/1)
- Qatar National Research Fund (7-1083-1-191)
- Horizon 2020 (671564, 675451)
- President and Provost's Office, University College London
This publication has 39 references indexed in Scilit:
- Clinical progress and pharmacology of small molecule bromodomain inhibitorsCurrent Opinion in Chemical Biology, 2016
- On the calculation of equilibrium thermodynamic properties from molecular dynamicsPhysical Chemistry Chemical Physics, 2016
- A Real-World Perspective on Molecular DesignJournal of Medicinal Chemistry, 2016
- Epigenetic Medicinal ChemistryACS Medicinal Chemistry Letters, 2015
- Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force FieldJournal of the American Chemical Society, 2015
- CURRENT PROGRESS IN STRUCTURE-BASED RATIONAL DRUG DESIGN MARKS A NEW MINDSET IN DRUG DISCOVERYComputational and Structural Biotechnology Journal, 2013
- Epigenetic protein families: a new frontier for drug discoveryNature Reviews Drug Discovery, 2012
- Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole SulfonamidesJournal of Medicinal Chemistry, 2012
- Computer-aided molecular design under the SWOTlightJournal of Computer-Aided Molecular Design, 2011
- Targeting epigenetic enzymes for drug discoveryCurrent Opinion in Chemical Biology, 2010